• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Zai Lab Stock Gets A Phase 3 Push After Positive Lung Cancer Trial Data

    Simply Wall St·10/24/2026 19:29:22
    Listen to the news
    • Zai Lab reported early Phase 1b results for zocilurtatug pelitecan with atezolizumab in first line extensive stage small cell lung cancer, with high objective response rates, encouraging PFS metrics and a tolerable safety profile across doublet and triplet regimens.
    • The company is moving toward a global Phase 3 program for zoci based on these data, which could reshape Zai Lab's oncology portfolio mix and future R&D spending priorities.
    • This article examines how Zai Lab's broader investment narrative is influenced by advancing zoci into global Phase 3 development.

    Scan beyond Zai Lab and compare this catalyst with other oncology focused opportunities by reviewing the curated 21 high quality undiscovered gems that could be flying under most investors' radar.

    Zai Lab Investment Narrative Recap

    To own Zai Lab, you need to believe the oncology and immunology pipeline can eventually turn strong forecast top line growth into sustainable earnings, despite the group being unprofitable and not expected to break even within three years. The zoci Phase 1b data supports the idea that internally developed assets could matter more over time than licensed products.

    In the near term, the key swing factor is clean execution as zoci moves into global Phase 3, while existing commercial drugs in China face competition, pricing pressure, and reimbursement uncertainty. The biggest current risk remains sustained high R&D and SG&A spending without a clear path to profitability.

    The US$250m private placement announced on 22 October sits alongside this zoci update and is highly relevant. Management plans to use the proceeds primarily for global development of the DLL3 antibody drug conjugate, including moving the ES SCLC program into Phase 3 and supporting broader clinical work around zoci combinations.

    For investors, that implies potential balance sheet support for an expanded trial footprint, but also more share issuance in a business that is still loss making. Execution risk around capital allocation may rise, since the potential payoff from heavier spending on zoci and the wider pipeline depends on trial quality, regulatory outcomes, and the ability to defend future pricing in China and abroad.

    Zai Lab's projections indicate revenue of US$832.0 million and earnings of US$157.9 million by 2029. This narrative is based on an assumed 22.4% annual revenue growth rate and an increase in earnings of about US$336.0 million from the current earnings level, which is a loss of US$178.1 million.

    Uncover why Zai Lab's fair value indicates a 39% potential upside to its current price. This discount could close more quickly than you might expect.

    NasdaqGM:ZLAB 1-Year Stock Price Chart
    NasdaqGM:ZLAB 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on Zai Lab leans heavily on Zoci as a future growth engine. The most optimistic analysts were already assuming 30.7% annual revenue growth, about US$1.0b of sales and US$160.5 million of earnings by 2029. You can treat this Phase 1b update as a fresh data point that might later shift those pre news assumptions, and you can explore how your own expectations line up with both the bullish and more cautious camps.

    Explore 3 other Zai Lab fair value estimates, including one that suggests as much as 239% upside from the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Zai Lab?

    Once you have a view on Zai Lab, it can help to cross check that thesis against a wider watchlist built from different styles of opportunities using the Simply Wall St Screener.

    • If you want potential mispricing paired with quality fundamentals, start by scanning our 27 high quality undervalued stocks that may offer a mix of resilient balance sheets and attractive valuations.
    • For investors who care most about capital strength and financial resilience, build a shortlist from the list of solid balance sheet and fundamentals (25 results) and focus on companies with robust fundamentals.
    • If you prefer ideas that the market may not be paying full attention to yet, broaden your radar with the 21 high quality undiscovered gems and see which profiles line up with your own return and risk preferences.